Novartis currently markets Lutathera (lutetium Lu 177 dotatate), an approved peptide receptor radionuclide therapy (PRRT) for SSTR-positive GEP-NETs. Sanofi has also entered the space, having ...

CAR-T therapy Kymriah (tisagenlecleucel) for leukaemia/lymphoma and radio-oncology drug Lutathera (lutetium Lu 177 dotatate) – with four more due in 2019. This year’s crop are predicted to be ...

The Swiss pharma group said it would continue to work with Siemens Healthineers to support and supply its radioligand therapies (RLTs), which include Lutathera (lutetium [Lu177] dotatate ...